FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2128332086> ?p ?o ?g. }

• W2128332086 endingPage "2869" @default.
• W2128332086 startingPage "2862" @default.
• W2128332086 abstract "Cisplatin and its analogues are the most commonly used agents in the treatment of head and neck squamous cell carcinoma. In this study, we investigated a possible role of epidermal growth factor (EGF) receptor (EGFR) phosphorylation and degradation in cisplatin-induced cytotoxicity. Cisplatin treatment led to an increase in initial EGFR phosphorylation at Y1045, the binding site of ubiquitin ligase, Casitas B-lineage lymphoma (c-Cbl), followed by ubiquitination in the relatively cisplatin-sensitive cell lines. However, cisplatin-resistant cell lines underwent minimal EGFR phosphorylation at the Y1045 site and minimal ubiquitination. We found that EGFR degradation in response to cisplatin was highly correlated with cytotoxicity in seven head and neck cancer cell lines. Pretreatment with EGF enhanced cisplatin-induced EGFR degradation and cytotoxicity, whereas erlotinib pretreatment blocked EGFR phosphorylation, degradation, and cisplatin-induced cytotoxicity. Expression of a mutant Y1045F EGFR, which is relatively resistant to c-Cbl-mediated degradation, in Chinese hamster ovary cells and the UMSCC11B human head and neck cancer cell line protected EGFR from cisplatin-induced degradation and enhanced cell survival compared with wild-type (WT) EGFR. Transfection of WT c-Cbl enhanced EGFR degradation and cisplatin-induced cytotoxicity compared with control vector. These results show that cisplatin-induced EGFR phosphorylation and subsequent ubiquitination and degradation is an important determinant of cisplatin sensitivity. Our findings suggest that treatment with an EGFR inhibitor before cisplatin would be antagonistic, as EGFR inhibition would protect EGFR from cisplatin-mediated phosphorylation and subsequent ubiquitination and degradation, which may explain the negative results of several recent clinical trials. Furthermore, they suggest that EGFR degradation is worth exploring as an early biomarker of response and as a target to improve outcome." @default.
• W2128332086 created "2016-06-24" @default.
• W2128332086 creator A5002172916 @default.
• W2128332086 creator A5016139703 @default.
• W2128332086 creator A5043006700 @default.
• W2128332086 creator A5046132413 @default.
• W2128332086 creator A5064396286 @default.
• W2128332086 creator A5065899903 @default.
• W2128332086 creator A5074986356 @default.
• W2128332086 creator A5083944057 @default.
• W2128332086 creator A5084941880 @default.
• W2128332086 creator A5089487611 @default.
• W2128332086 date "2010-03-31" @default.
• W2128332086 modified "2023-10-05" @default.
• W2128332086 title "Role of Epidermal Growth Factor Receptor Degradation in Cisplatin-Induced Cytotoxicity in Head and Neck Cancer" @default.
• W2128332086 cites W1501621869 @default.
• W2128332086 cites W1529786888 @default.
• W2128332086 cites W1965186484 @default.
• W2128332086 cites W1968366677 @default.
• W2128332086 cites W1973794764 @default.
• W2128332086 cites W1983660720 @default.
• W2128332086 cites W2004759810 @default.
• W2128332086 cites W2010649544 @default.
• W2128332086 cites W2012733679 @default.
• W2128332086 cites W2012936999 @default.
• W2128332086 cites W2016320036 @default.
• W2128332086 cites W2023288925 @default.
• W2128332086 cites W2026177159 @default.
• W2128332086 cites W2032359283 @default.
• W2128332086 cites W2036005555 @default.
• W2128332086 cites W2039140611 @default.
• W2128332086 cites W2041875984 @default.
• W2128332086 cites W2048168597 @default.
• W2128332086 cites W2059128931 @default.
• W2128332086 cites W2076892378 @default.
• W2128332086 cites W2083215308 @default.
• W2128332086 cites W2088696453 @default.
• W2128332086 cites W2094882473 @default.
• W2128332086 cites W2107277218 @default.
• W2128332086 cites W2111693820 @default.
• W2128332086 cites W2120085428 @default.
• W2128332086 cites W2121158863 @default.
• W2128332086 cites W2122185071 @default.
• W2128332086 cites W2123555204 @default.
• W2128332086 cites W2130177169 @default.
• W2128332086 cites W2134423418 @default.
• W2128332086 cites W2134964659 @default.
• W2128332086 cites W2139404289 @default.
• W2128332086 cites W2144233480 @default.
• W2128332086 cites W2145842917 @default.
• W2128332086 cites W2147675788 @default.
• W2128332086 cites W2169290377 @default.
• W2128332086 cites W2171578197 @default.
• W2128332086 cites W2192080449 @default.
• W2128332086 cites W2329407609 @default.
• W2128332086 cites W2562414697 @default.
• W2128332086 cites W1778748344 @default.
• W2128332086 doi "https://doi.org/10.1158/0008-5472.can-09-4294" @default.
• W2128332086 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2848889" @default.
• W2128332086 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20215522" @default.
• W2128332086 hasPublicationYear "2010" @default.
• W2128332086 type Work @default.
• W2128332086 sameAs 2128332086 @default.
• W2128332086 citedByCount "68" @default.
• W2128332086 countsByYear W21283320862012 @default.
• W2128332086 countsByYear W21283320862013 @default.
• W2128332086 countsByYear W21283320862014 @default.
• W2128332086 countsByYear W21283320862015 @default.
• W2128332086 countsByYear W21283320862016 @default.
• W2128332086 countsByYear W21283320862017 @default.
• W2128332086 countsByYear W21283320862018 @default.
• W2128332086 countsByYear W21283320862019 @default.
• W2128332086 countsByYear W21283320862020 @default.
• W2128332086 countsByYear W21283320862021 @default.
• W2128332086 countsByYear W21283320862022 @default.
• W2128332086 crossrefType "journal-article" @default.
• W2128332086 hasAuthorship W2128332086A5002172916 @default.
• W2128332086 hasAuthorship W2128332086A5016139703 @default.
• W2128332086 hasAuthorship W2128332086A5043006700 @default.
• W2128332086 hasAuthorship W2128332086A5046132413 @default.
• W2128332086 hasAuthorship W2128332086A5064396286 @default.
• W2128332086 hasAuthorship W2128332086A5065899903 @default.
• W2128332086 hasAuthorship W2128332086A5074986356 @default.
• W2128332086 hasAuthorship W2128332086A5083944057 @default.
• W2128332086 hasAuthorship W2128332086A5084941880 @default.
• W2128332086 hasAuthorship W2128332086A5089487611 @default.
• W2128332086 hasBestOaLocation W21283320861 @default.
• W2128332086 hasConcept C109316439 @default.
• W2128332086 hasConcept C11960822 @default.
• W2128332086 hasConcept C121608353 @default.
• W2128332086 hasConcept C170493617 @default.
• W2128332086 hasConcept C185592680 @default.
• W2128332086 hasConcept C202751555 @default.
• W2128332086 hasConcept C2776530083 @default.
• W2128332086 hasConcept C2776694085 @default.
• W2128332086 hasConcept C2776833033 @default.
• W2128332086 hasConcept C2778239845 @default.
• W2128332086 hasConcept C2779438470 @default.

• next